Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless ofhydroxycarbamide therapy

Experimental Hematology

Volumn 41, Issue 7, 2013, Pages 627-634

  Ruella, Marco ^a,b   Salmoiraghi, Silvia ^c   Risso, Alessandra ^b   Carobbio, Alessandra ^c   Buttiglieri, Stefano ^b   Spatola, Tiziana ^b   Sivera, Piera ^a   Ricca, Irene ^d   Barbui, Tiziano ^c   Tarella, Corrado ^a,b   Rambaldi, Alessandro ^c  

^a MAURIZIANO HOSPITAL   (Italy)

^b Molecular Biotechnology Center   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d Ospedale Cottolengo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; HYDROXYUREA; INTERFERON; JANUS KINASE 2; PIPOBROMAN;

ADOLESCENT; ADULT; AGE; AGED; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SCHOOL CHILD; SECONDARY ERYTHROCYTOSIS; TELOMERE; TELOMERE SHORTENING; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CLONE CELLS; FEMALE; HUMANS; HYDROXYUREA; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; TELOMERE; YOUNG ADULT;

EID: 84879606346     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.03.007     Document Type: Article

References (51)

1. Blackburn E.H. Structure and function of telomeres. Nature 1991, 350:569-573.
2. Zakian V.A. Telomeres: beginning to understand the end. Science 1995, 270:1601-1607.
3. van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998, 92:401-413.
4. Griffith J.D., Comeau L., Rosenfield S., et al. Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503-514.
5. Lansdorp P.M. Telomeres, stem cells, and hematology. Blood 2008, 111:1759-1766.
6. de Lange T., Shiue L., Myers R.M., et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990, 10:518-527.
7. Martens U.M., Chavez E.A., Poon S.S., Schmoor C., Lansdorp P.M. Accumulation of short telomeres in human fibroblasts prior to replicative senescence. Exp Cell Res 2000, 256:291-299.
8. Greider C.W. Telomeres, telomerase and senescence. Bioessays 1990, 12:363-369.
9. Harley C.B. Telomere loss: Mitotic clock or genetic time bomb?. Mutat Res 1991, 256:271-282.
10. Lindsey J., McGill N.I., Lindsey L.A., Green D.K., Cooke H.J. Invivo loss of telomeric repeats with age in humans. Mutat Res 1991, 256:45-48.
11. Allsopp R.C., Vaziri H., Patterson C., et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992, 89:10114-10118.
12. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., Allshire R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990, 346:866-868.
13. Vaziri H., Schachter F., Uchida I., et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993, 52:661-667.
14. Furugori E., Hirayama R., Nakamura K.I., Kammori M., Esaki Y., Takubo K. Telomere shortening in gastric carcinoma with aging despite telomerase activation. J Cancer Res Clin Oncol 2000, 126:481-485.
15. Hartmann U., Brummendorf T.H., Balabanov S., Thiede C., Illme T., Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005, 90:307-316.
16. Kubuki Y., Suzuki M., Sasaki H., et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005, 46:393-399.
17. Kleideiter E., Bangerter U., Schwab M., et al. Telomeres and telomerase in paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL). Leukemia 2005, 19:296-298.
18. Ohyashiki K., Ohyashiki J.H., Fujimura T., et al. Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Genet Cytogenet 1994, 78:64-67.
19. Ohyashiki J.H., Iwama H., Yahata N., et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999, 5:1155-1160.
20. Ricca I., Rocci A., Drandi D., et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007, 21:697-705.
21. Lobetti-Bodoni C., Bernocco E., Genuardi E., Boccadoro M., Ladetto M. Telomeres and telomerase in normal and malignant B-cells. Hematol Oncol 2010, 28:157-167.
22. Wentzensen I.M., Mirabello L., Pfeiffer R.M., Savage S.A. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011, 20:1238-1250.
23. Widmann T.A., Herrmann M., Taha N., Konig J., Pfreundschuh M. Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis. Exp Hematol 2007, 35:939-946.
24. Boultwood J., Peniket A., Watkins F., et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000, 96:358-361.
25. Engelhardt M., Mackenzie K., Drullinsky P., Silver R.T., Moore M.A. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-exvivo culture. Cancer Res 2000, 60:610-617.
26. Terasaki Y., Okumura H., Ohtake S., Nakao S. Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol 2002, 30:1399-1404.
27. Samassekou O., Ntwari A., Hebert J., Yan J. Individual telomere lengths in chronic myeloid leukemia. Neoplasia 2009, 11:1146-1154.
28. Keller G., Brassat U., Braig M., Heim D., Wege H., Brummendorf T.H. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematol Oncol 2009, 27:123-129.
29. Drummond M., Lennard A., Brummendorf T., Holyoake T. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma 2004, 45:1775-1781.
30. Brummendorf T.H., Ersoz I., Hartmann U., et al. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. Blood 2003, 101:375-376.
31. Ohyashiki K., Iwama H., Tauchi T., et al. Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia. Leuk Lymphoma 2000, 40:49-56.
32. Brummendorf T.H., Balabanov S. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 2006, 20:1706-1716.
33. Bernard L., Belisle C., Mollica L., et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia 2009, 23:287-291.
34. Ferraris A.M., Mangerini R., Pujic N., et al. High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. Blood 2005, 105:2138-2140.
35. Spanoudakis E., Bazdiara I., Pantelidou D., et al. Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res 2011, 35:459-464.
36. Ruella M., Rocci A., Ricca I., et al. Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplant 2010, 45:505-512.
37. Hultdin M., Gronlund E., Norrback K., Eriksson-Lindstrom E., Just T., Roos G. Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res 1998, 26:3651-3656.
38. Swierczek S.I., Piterkova L., Jelinek J., et al. Methylation of AR locus does not always reflect X chromosome inactivation state. Blood 2012, 119:e100-e109.
39. Busque L., Paquette Y., Provost S., et al. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood 2009, 113:3472-3474.
40. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
41. Guerini V., Barbui V., Spinelli O., et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008, 22:740-747.
42. Pardanani A., Lasho T.L., Finke C., Hanson C.A., Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007, 21:1960-1963.
43. Ferraris A.M., Pujic N., Mangerini R., et al. Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres. Br J Haematol 2005, 130:391-393.
44. Elena C., Rumi E., Portolan M., Della Porta M.G., Pascutto C., Passamonti F. Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. Haematologica 2011, 96:1236-1238.
45. Barbui T., Barosi G., Birgegard G., et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011, 29:761-770.
46. Shay J.W., Wright W.E. Role of telomeres and telomerase in cancer. Semin Cancer Biol 2011, 21:349-353.
47. Kiladjian J.-J., Chevret S., Dosquet C., Chomienne C., Rain J.-D. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011, 29:3907-3913.
48. Bjorkholm M., Derolf A.R., Hultcrantz M., et al. Treatment-related riskfactors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011, 29:2410-2415.
49. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. NEngl J Med 2010, 363:1117-1127.
50. Pardanani A., Gotlib J.R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789-796.
51. Chakraborty S., Sun C.L., Francisco L., et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009, 27:791-798.